ANDA Litigation Soars In 2014-2015; Patent Office Petitions Also Jump
This article was originally published in The Pink Sheet Daily
Purdue's OxyContin and Amarin's Vascepa lead the list of targets as an increasing number of generic firms take up litigation.
You may also be interested in...
ANDA Case Filings Drop 32%, But Still High Compared To Last Decade
Lex Machina reports that 316 ANDA cases were filed in 2016 compared to 468 in 2015; number of inter partes review petitions filed on Orange Book patents has declined since 2015.
Brand vs. Brand Patent Battles Heat Up, Focus On Big Drug Classes
Patent brawl between Merck and Gilead involving Sovaldi and Harvoni was one of the marquee litigation events of 2016; a compilation of disputes between brand-name companies over the past six years shows how consequential they can be.
Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages
Teva and Sun are to pay $2.15 billion for their at-risk launch of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.